文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒特殊人群用药

自闭症儿童青少年阿立哌唑精准给药:血药浓度与体重增加及疗效的关联

Towards precision dosing of aripiprazole in children and adolescents with autism spectrum disorder: Linking blood levels to weight gain and effectiveness.
PubMed 文献 · Br J Clin Pharmacol · 2023-06-13

本研究在24例6-18岁自闭症谱系障碍伴行为问题的儿童青少年中开展24周前瞻性观察,采用群体药代动力学模型分析阿立哌唑及其活性代谢物浓度与BMI等指标的关系。发现阿立哌唑与脱氢阿立哌唑谷浓度之和越高,BMI z评分(P<.001)和HbA1c水平(P=.03)越高,但与疗效无显著关联,提示治疗药物监测可能提高安全性。

要点

  • 阿立哌唑与脱氢阿立哌唑谷浓度之和越高,BMI z评分和HbA1c水平越高。
  • 谷浓度之和与药物有效性无显著关联。
  • 治疗药物监测可能有助于提高自闭症儿童青少年用药安全性。

核心结论

  • 阿立哌唑与脱氢阿立哌唑谷浓度之和越高,BMI z评分和HbA1c水平越高,提示安全性存在阈值。
  • 谷浓度之和与药物有效性无显著关联。
  • 治疗药物监测可能提高自闭症谱系障碍伴行为问题儿童青少年使用阿立哌唑的安全性。

研究设计与样本

  • 24周前瞻性观察性试验,纳入24例6-18岁自闭症谱系障碍伴行为问题的儿童青少年(15男9女)。
  • 测定CYP2D6、CYP3A4、CYP3A5和P-糖蛋白(ABCB1)基因型等药代动力学协变量。
  • 采用非线性混合效应模型(NONMEM®)分析92个阿立哌唑浓度和91个脱氢阿立哌唑浓度。

主要发现

  • 阿立哌唑和脱氢阿立哌唑均以一室模型最佳描述,白蛋白和BMI为显著协变量。
  • 阿立哌唑与脱氢阿立哌唑谷浓度之和越高,随访期间BMI z评分越高(P<.001)。
  • 谷浓度之和越高,HbA1c水平越高(P=.03)。
  • 谷浓度之和与药物有效性无显著关联。

临床怎么用

  • 对自闭症谱系障碍伴行为问题的儿童青少年使用阿立哌唑时,可考虑监测阿立哌唑与脱氢阿立哌唑谷浓度之和以评估体重增加和血糖风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Aripiprazole is one of the most commonly prescribed antipsychotic drugs to children and adolescents worldwide, but it is associated with serious side-effects, including weight gain. This study assessed the population pharmacokinetics of aripiprazole and its active metabolite and investigated the relationship between pharmacokinetic parameters and body mass index (BMI) in children and adolescents with autism spectrum disorder (ASD) and behavioural problems. Secondary outcomes were metabolic, endocrine, extrapyramidal and cardiac side-effects and drug effectiveness. METHODS: Twenty-four children and adolescents (15 males, 9 females) aged 6-18 years were included in a 24-week prospective observational trial. Drug plasma concentrations, side-effects and drug effectiveness were measured at several time points during follow-up. Relevant pharmacokinetic covariates, including CYP2D6, CYP3A4, CYP3A5 and P-glycoprotein (ABCB1) genotypes, were determined. Nonlinear mixed-effects modelling (NONMEM®) was used for a population pharmacokinetic analysis with 92 aripiprazole and 91 dehydro-aripiprazole concentrations. Subsequently, model-based trough concentrations, maximum concentrations and 24-h area under the curves (AUCs) were analysed to predict outcomes using generalized and linear mixed-effects models. RESULTS: For both aripiprazole and dehydro-aripiprazole, one-compartment models best described the measured concentrations, with albumin and BMI as significant covariates. Of all the pharmacokinetic parameters, higher sum (aripiprazole plus dehydro-aripiprazole) trough concentrations best predicted higher BMI z-scores (P < .001) and higher Hb1Ac levels (P = .03) during follow-up. No significant association was found between sum concentrations and effectiveness. CONCLUSIONS: Our results indicate a threshold with regard to safety, which suggests that therapeutic drug monitoring of aripiprazole could potentially increase safety in children and adolescents with ASD and behavioural problems.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Hermans RA, Sassen SDT, Kloosterboer SM, et al. Towards precision dosing of aripiprazole in children and adolescents with autism spectrum disorder: Linking blood levels to weight gain and effectiveness. Br J Clin Pharmacol. 2023. PMID: 37222228. doi:10.1111/bcp.15800

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。